Literature DB >> 4376804

Infection of EBV-genome-negative and -positive human lymphoblastoid cell lines with biologically different preparations of EBV.

G Klein, B Sugden, W Leibold, J Menezes.   

Abstract

Epstein-Barr virus (EBV) derived from the B95-8 line has transforming activity for cord blood cells, whereas virus derived from the P3HR-1 line lacks such activity. When the two viral preparations were compared for their ability to infect the same EBV-genome-negative lymphoblastoid cell line, BJA-B, they induced approximately the same number of EBV-determined nuclear antigen (EBNA)-positive cells. EBNA is compatibile with continued cell proliferation. No early antigen (EA)-positive cells appeared in the B95-8 virus-infected cultures, whereas P3HR-1 virus-infected cells went on to express EA. EA signals the entry of the cell into the lytic cycle. No late viral antigen (VCA) appeared and, as a consequence, the P3HR-1 virus infection became abortive. In contrast, the EBNA-positive cells induced by the B95-8 virus continued to divide over several weeks. These findings show that different EBV isolates may differ in their biological activity, probably due to their having different degrees of viral dependence on restrictive host cell controls.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4376804     DOI: 10.1159/000149760

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  16 in total

1.  Discordance of Epstein-Barr Virus (EBV) specific humoral and cellular immunity in patients with malignant lymphomas: elevated antibody titres and lowered in vitro lymphocyte reactivity.

Authors:  C H Ten Napel; T H The; J Van Egten-Bijker; G C de Gast; M R Halie; M M Langenhuysen
Journal:  Clin Exp Immunol       Date:  1978-12       Impact factor: 4.330

2.  Nucleic acid renaturation and restriction endonuclease cleavage analyses show that the DNAs of a transforming and a nontransforming strain of Epstein-Barr virus share approximately 90% of their nucleotide sequences.

Authors:  B Sugden; W C Summers; G Klein
Journal:  J Virol       Date:  1976-05       Impact factor: 5.103

3.  Infectious mononucleosis and mononucleosis syndromes.

Authors:  M Fiala; D C Heiner; J A Turner; B Rosenbloom; L B Guze
Journal:  West J Med       Date:  1977-06

4.  Mechanisms of infection with Epstein-Barr virus. I. Viral DNA replication and formation of noninfectious virus particles in superinfected Raji cells.

Authors:  Y Yajima; M Nonoyama
Journal:  J Virol       Date:  1976-07       Impact factor: 5.103

5.  Large-scale production and concentration of infectious Epstein-Barr virus.

Authors:  F Klein; J F Rosensteel; R M Hummer; E A Hillman; C W Riggs; L J Charmella
Journal:  Appl Environ Microbiol       Date:  1978-01       Impact factor: 4.792

6.  A routine method for the establishment of permanent growing lymphoblastoid cell lines.

Authors:  H Neitzel
Journal:  Hum Genet       Date:  1986-08       Impact factor: 4.132

7.  Stimulation of a human B-lymphocyte line by anti-immunoglobulin and its concanavalin A-induced suppression by a T-cell line.

Authors:  T Kishimoto; P Ralph; R A Good
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

8.  Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV.

Authors:  N Shimizu; A Tanabe-Tochikura; Y Kuroiwa; K Takada
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphoid tissues.

Authors:  I S Trowbridge; J Lesley; R Schulte; R Hyman; J Trotter
Journal:  Immunogenetics       Date:  1982-03       Impact factor: 2.846

10.  Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA1: implications of the nuclear import of plasmids.

Authors:  F Längle-Rouault; V Patzel; A Benavente; M Taillez; N Silvestre; A Bompard; G Sczakiel; E Jacobs; K Rittner
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.